Market
What milestone will Gilead's STAT6 drug achieve in 2025?
2
Resolution / Starting Odds
Phase II trial completion • 25%
Phase III trial initiation • 25%
FDA approval • 25%
No significant milestone • 25%
Official announcements from Gilead Sciences or LEO Pharma
Story
Gilead Sciences Partners with LEO Pharma, Paying $250M for Oral Drug Targeting STAT6 in Inflammatory Diseases
Jan 11, 2025, 05:03 PM
Gilead Sciences has entered into a strategic partnership with LEO Pharma, focusing on the development of an oral drug targeting STAT6, which has potential applications in treating various inflammatory diseases. As part of the agreement, Gilead will pay LEO Pharma $250 million upfront to license the drug. This collaboration aims to accelerate the development of the STAT6 program, which is expected to address unmet medical needs in the field of inflammatory diseases.
View original story
Similar markets
FDA Fast Track designation • 25%
Phase 2 initiation • 25%
None of the above • 25%
Positive Phase 1 results • 25%
Phase 3 completion • 25%
No significant milestone • 25%
Phase 2 completion • 25%
Phase 1 completion • 25%
Not approved in US or EU • 25%
Approved in both US and EU • 25%
Approved in EU • 25%
Approved in US • 25%
No • 50%
Yes • 50%
Positive efficacy and safety results • 25%
Negative efficacy and safety concerns • 25%
Negative efficacy, but good safety • 25%
Positive efficacy, but safety concerns • 25%
Approved in UK, EU, and USA • 25%
Not approved in any major market • 25%
Approved in UK and EU • 25%
Approved in UK only • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
$500 million to $1 billion • 25%
Less than $500 million • 25%
10% to 15% increase • 25%
More than 15% increase • 25%
Less than 5% increase • 25%
5% to 10% increase • 25%
Focus on internal development • 25%
Another acquisition in oncology • 25%
Partnership with another biotech • 25%
Other strategic move • 25%
